Compare KTCC & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTCC | TIL |
|---|---|---|
| Founded | 1969 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.2M | 48.4M |
| IPO Year | 1995 | 2021 |
| Metric | KTCC | TIL |
|---|---|---|
| Price | $3.94 | $7.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 9.5K | ★ 9.7K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.06 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $467,871,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.40 | $5.67 |
| 52 Week High | $4.42 | $33.83 |
| Indicator | KTCC | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 50.73 | 39.06 |
| Support Level | $3.82 | $6.85 |
| Resistance Level | $4.10 | $8.30 |
| Average True Range (ATR) | 0.21 | 0.16 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 49.15 | 25.38 |
Key Tronic Corporation provides electronic manufacturing services, including engineering, materials management, manufacturing and assembly, in-house testing, and distribution to various countries. The company serves diverse industries such as pest control, personal protection, air purification, automotive, medical technology, and utilities inspection equipment. Its primary services include integrated electronic and mechanical engineering, precision plastic molding, sheet metal fabrication, printed circuit board (PCB) and complete product assembly. Key Tronic operates manufacturing facilities in the United States, Vietnam, and Mexico, recently expanding with a new facility in Arkansas. Revenue is generated mainly through contract manufacturing and service agreement.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.